Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.

Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J.

J Clin Oncol. 2016 Jan 10;34(2):139-43. doi: 10.1200/JCO.2015.63.4972. Epub 2015 Nov 23.


Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.


Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.

Sestak I, Sapunar F, Cuzick J.

J Clin Oncol. 2009 Oct 20;27(30):4961-5. doi: 10.1200/JCO.2009.22.0236. Epub 2009 Sep 14.


Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.


Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, R├╝cklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.


Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators.

Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum in: Lancet. 2014 Mar 22;383(9922):1040. Lancet. 2017 Mar 11;389(10073):1010.


Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU; ATAC Trialists' Group.

Lancet Oncol. 2008 Sep;9(9):866-72. doi: 10.1016/S1470-2045(08)70182-7. Epub 2008 Aug 12.


Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).

Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ.

Lancet Oncol. 2008 Oct;9(10):953-61. doi: 10.1016/S1470-2045(08)70207-9. Epub 2008 Sep 1.


Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group.

J Bone Miner Res. 2006 Aug;21(8):1215-23.


Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.


Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.

Singh S, Cuzick J, Mesher D, Richmond B, Howell A.

Breast Cancer Res Treat. 2012 Apr;132(2):625-9. doi: 10.1007/s10549-011-1911-6. Epub 2011 Dec 25.


Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.

Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.


Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J.

Breast Cancer Res Treat. 2012 Jul;134(2):727-34. doi: 10.1007/s10549-012-2085-6. Epub 2012 May 16.


Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

Doggrell SA.

Expert Opin Pharmacother. 2008 Jun;9(9):1619-22. doi: 10.1517/14656566.9.9.1619 .


Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators.

Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29.


Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.

Nishihori T, Choi J, DiGiovanna MP, Thomson JG, Kohler PC, McGurn J, Chung GG.

Clin Breast Cancer. 2008 Aug;8(4):362-5. doi: 10.3816/CBC.2008.n.043.


Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.

Nabholtz JM.

Am J Hosp Palliat Care. 2004 Nov-Dec;21(6):457-65. Review.


Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?

Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM.

Tumori. 2015 Sep-Oct;101(5):469-73. doi: 10.5301/tj.5000376. Epub 2015 Jun 13.


Supplemental Content

Support Center